TY - JOUR
T1 - De waarde van positronemissietomografie bij de diagnostiek en behandeling van het oesofaguscarcinoom
AU - Omloo, J. M. T.
AU - Westerterp, M.
AU - Sloof, G. W.
AU - Hoekstra, O. S.
AU - van Lanschot, J. J. B.
PY - 2008/2/16
Y1 - 2008/2/16
N2 - - Fludeoxyglucose positron emission tomography (FDG-PET) is a non-invasive imaging technique that applies the glucose metabolism to visualise the metabolic activity of a tumour. - FDG-PET might improve the selection of potentially curable patients with oesophageal cancer in addition to state-of-the-art conventional work-up (e.g. endoscopic ultrasonography and spiral CT). The additional value however is only 4% for all patients, and 7% in patients with stage III-IV disease. Moreover, the additional costs of FDG-PET are not compensated by the cost reduction of prevented surgery. - To improve the outcome of patients with oesophageal cancer the value of neoadjuvant chemo- and/or radiotherapy is being investigated. FDG-PET seems to be a promising tool for the early assessment of response to neoadjuvant therapy. In case of non-response the ineffective neoadjuvant therapy can be stopped without further delaying appropriate surgery. - FDG-PET might be able to improve the prediction of prognosis, in addition to commonly used histopathological factors.
AB - - Fludeoxyglucose positron emission tomography (FDG-PET) is a non-invasive imaging technique that applies the glucose metabolism to visualise the metabolic activity of a tumour. - FDG-PET might improve the selection of potentially curable patients with oesophageal cancer in addition to state-of-the-art conventional work-up (e.g. endoscopic ultrasonography and spiral CT). The additional value however is only 4% for all patients, and 7% in patients with stage III-IV disease. Moreover, the additional costs of FDG-PET are not compensated by the cost reduction of prevented surgery. - To improve the outcome of patients with oesophageal cancer the value of neoadjuvant chemo- and/or radiotherapy is being investigated. FDG-PET seems to be a promising tool for the early assessment of response to neoadjuvant therapy. In case of non-response the ineffective neoadjuvant therapy can be stopped without further delaying appropriate surgery. - FDG-PET might be able to improve the prediction of prognosis, in addition to commonly used histopathological factors.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=39649090286&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/18380382
M3 - Article
C2 - 18380382
SN - 0028-2162
VL - 152
SP - 365
EP - 370
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
IS - 7
ER -